Growing community of inventors

Okayama, Japan

Yasutomo Nasu

Average Co-Inventor Count = 4.61

ph-index = 3

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 23

Yasutomo NasuHiromi Kumon (7 patents)Yasutomo NasuMasakiyo Sakaguchi (4 patents)Yasutomo NasuMasami Watanabe (4 patents)Yasutomo NasuNam-Ho Huh (4 patents)Yasutomo NasuYuji Kashiwakura (3 patents)Yasutomo NasuFernando Guillermo Abarzua Cabezas (2 patents)Yasutomo NasuChae Ok Yun (1 patent)Yasutomo NasuKensuke Kawasaki (1 patent)Yasutomo NasuYasutomo Nasu (7 patents)Hiromi KumonHiromi Kumon (15 patents)Masakiyo SakaguchiMasakiyo Sakaguchi (9 patents)Masami WatanabeMasami Watanabe (8 patents)Nam-Ho HuhNam-Ho Huh (5 patents)Yuji KashiwakuraYuji Kashiwakura (3 patents)Fernando Guillermo Abarzua CabezasFernando Guillermo Abarzua Cabezas (2 patents)Chae Ok YunChae Ok Yun (18 patents)Kensuke KawasakiKensuke Kawasaki (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Momotaro-gene Inc. (4 from 10 patents)

2. Other (3 from 832,880 patents)

3. Okayama University (2 from 136 patents)

4. Industry-University Cooperation Foundation Hanyang University (1 from 1,115 patents)

5. Kumon, Hiromi (0 patent)

6. Sakaguchi, Masakiyo (0 patent)

7. Abarzua Cabezas, Fernando Guillermo (0 patent)

8. Nasu, Yasutomo (0 patent)

9. Huh, Nam-ho (0 patent)


7 patents:

1. 10071126 - Conditionally replicating adenovirus to express REIC gene

2. 9475865 - Direct administration of REIC/Dkk-3 to mesothelioma

3. 8946173 - Cancer cell death inducing agent having effects of potentiating anticancer drug against anticancer-drug-resistant cancer

4. 8658611 - Apoptosis-inducing agent for prostate cancer cells

5. 8658612 - Therapeutic agent for malignant mesothelioma and immunostimulant

6. 8618273 - Partial fragment of REIC/Dkk-3 gene and cancer therapeutic agent comprising the same

7. 8614093 - Pharmaceutical composition for treating or preventing cancer by inducing dendritic cell-like differentiation from monocytes to improve anticancer immune activity

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
1/4/2026
Loading…